Experienced in Infantile Neutropenia

Dr. Mark D. Pegram

Oncology | Hematology Oncology | Surgical Oncology
900 Blake Wilbur Dr, First Floor, 
Palo Alto, CA 
Experienced in Infantile Neutropenia
900 Blake Wilbur Dr, First Floor, 
Palo Alto, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Pegram is an Oncologist and a Hematologist Oncology provider in Palo Alto, California. Dr. Pegram is rated as an Experienced provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast.

His clinical research consists of co-authoring 86 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Infantile Neutropenia.

Specialties
Oncology
Hematology Oncology
Surgical Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Santa Clara Family Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Valley Health
  • HMO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

900 Blake Wilbur Dr, First Floor, Palo Alto, CA 94304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
A Single Arm, Open-Label, Phase 2 Study of MGAH22 (Fc-optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients With Relapsed or Refractory Advanced Breast Cancer Whose Tumors Express HER2 at the 2+ Level by Immunohistochemistry and Lack Evidence of HER2 Gene Amplification by FISH
A Single Arm, Open-Label, Phase 2 Study of MGAH22 (Fc-optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients With Relapsed or Refractory Advanced Breast Cancer Whose Tumors Express HER2 at the 2+ Level by Immunohistochemistry and Lack Evidence of HER2 Gene Amplification by FISH
Enrollment Status: Completed
Publish Date: March 13, 2025
Intervention Type: Biological
Study Phase: Phase 2
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
Enrollment Status: Completed
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drug: ZW49
Study Phase: Phase 1
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: December 15, 2022
Intervention Type: Drug
Study Drugs: G1T48, Palbociclib
Study Phase: Phase 1
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Enrollment Status: Completed
Publish Date: April 15, 2022
Intervention Type: Procedure, Drug
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
View 5 Less Clinical Trials

86 Total Publications

Spontaneous upregulation of stemness and 3D spheroid formation of single cancer cells induced by scaffold-free polypeptide polyelectrolyte multilayer coating.
Spontaneous upregulation of stemness and 3D spheroid formation of single cancer cells induced by scaffold-free polypeptide polyelectrolyte multilayer coating.
Journal: Biomaterials
Published: July 08, 2025
Similar Doctors
Experienced in Infantile Neutropenia
Dr. William Shomali
Hematology | Oncology | Hematology Oncology
Experienced in Infantile Neutropenia
Dr. William Shomali
Hematology | Oncology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.2 miles away)
650-723-4000
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

William Shomali is a Hematologist and an Oncologist in Stanford, California. Dr. Shomali has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Systemic Mastocytosis, Mast Cell Activation Syndrome (MCAS), Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Bone Marrow Aspiration.

Experienced in Infantile Neutropenia
Dr. Lori S. Muffly
Hematology | Oncology | Hematology Oncology
Experienced in Infantile Neutropenia
Dr. Lori S. Muffly
Hematology | Oncology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.2 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lori Muffly is a Hematologist and an Oncologist in Stanford, California. Dr. Muffly is rated as an Elite provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Transplant, and Bone Graft.

Experienced in Infantile Neutropenia
Dr. Katherine K. Matthay
Pediatrics | Hematology
Experienced in Infantile Neutropenia
Dr. Katherine K. Matthay
Pediatrics | Hematology
505 Parnassus Ave, 
San Francisco, CA 
 (27.3 miles away)
415-476-3831
Languages Spoken:
English
See accepted insurances

Katherine Matthay is a Pediatrics specialist and a Hematologist in San Francisco, California. Dr. Matthay is rated as a Distinguished provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, Infantile Neutropenia, Thrombocytopenia, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pegram's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile